Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity

University of Copenhagen

Status: Completed

Conditions: Angiotensin-Converting Enzyme Inhibitors; Exercise

Treatments: Drug: Enalapril; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03949075

H-18016341

Details and patient eligibility

About

The phenotype based on the insertion/deletion (I/D) polymorphism of the human angiotensin converting enzyme (ACE) gene has been associated with individual training response. Briefly, intervention studies have demonstrated an 11-fold greater training-induced improvement in muscular endurance for ACE I/I homozygotes compared to ACE D/D homozygotes.

Importantly, the ACE I/D polymorphism causes large inter-individual differences in serum ACE activity. Because the ACE D/D genotype is characterized by high plasma ACE activity and potentially blunted endurance exercise training response, it appears likely that ACE inhibitors (ACEi) have the potential to improve the outcome of exercise training for ACE D/D homozygotes.

Thus, in the present study the investigators apply a randomized double-blind placebo-controlled longitudinal design to investigate whether pharmacological inhibition of ACE activity can amplify the exercise training response in healthy humans carrying either the ACE D/D or ACE I/I genotype.

The study hypothesis is that inhibition of ACE activity in healthy humans with the ACE D/D genotype will amplify the health beneficial effects of exercise training while this is not the case in ACE I/I homozygotes.

Enrollment: 52 patients

Sex: All

Ages: 20 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged 20-50 years
• Healthy

Exclusion criteria

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

52 participants in 2 patient groups, including a placebo group

Enalapril treatment

Experimental group

Treatment:

Drug: Enalapril

Placebo treatment

Placebo Comparator group

Treatment:

Drug: Placebo